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Summary 
Interlenkin 5 (IL-5) is the main factor that promotes the terminal differentiation  of eosinophil 
progenitors (as indicated by colony formation assays), and enhances the effector capacity of mature 
eosinophils.  IL-5 is produced by T  lymphocytes,  CD4-/CD8-  and mast  cells and recently, 
messenger (m)RNA of this cytokine has been identified in eosinophils from patients with coeliac 
disease, asthma, or eosinophilic heart diseases. In this study, IL-5 mRNA and immunoreactive 
IL-5 protein were detected in tissue and blood eosinophils from patients with eosinophilic cystitis 
or hypereosinophilic  syndromes but not in Crohn's disease. By electron microscopy associated 
to immunogold staining,  immunoreactive IL-5 was identified in eosinophilic  granules.  After 
stimulation with IgA-, IgE-, or IgG-immune complexes, blood eosinophils were shown, by 
immunocytochemistry and by enzyme-linked immunosorbent assay, to  secrete IL-5.  These 
observations demonstrate that eosinophils, under physiological stimulation, can release significant 
amounts of IL-5, which may contribute to local eosinophil  recruitment and activation. 
T  lymphocytes play a central role in eosinophil produc- 
tion, differentiation,  and function through the release 
of soluble mediators. A number of cytokines with selective 
action on eosinophils has been cloned and sequenced. Among 
those,  IL-5 is the main factor that promotes the terminal 
differentiation of the committed eosinophil precursors (1) and 
that enhances the effector capacity of mature eosinophils (2). 
Whereas IL-5 production by T cells has been well documented, 
mRNA for IL-5 also has been identified in mast cells (3) and 
more recently in eosinophils from patients with coeliac dis- 
ease (4), as well as in alveolar eosinophils from asthmatic pa- 
tients (5) or tissue eosinophils from patients with eosinophih'c 
heart diseases (6). However, until now, no evidence for the 
subcellular localization and secretion of IL-5 protein by eo- 
sinophils was presented. 
The aim of this study was to examine the presence of im- 
munoreactive IL-5 in tissue eosinophils from patients with 
a massive eosinophil infiltration associated to cystitis or Crohn's 
disease, as well as in blood eosinophils from patients  with 
hypereosinophilic syndromes. Immunogold staining was used 
to determine the subcellular localization  of IL-5.  Using a 
specific immunoenzymatic technique, the release of IL-5 was 
evaluated after incubation of eosinophils with various immune 
complexes. Our results show that immunoreactive IL-5 pro- 
tein, localized in eosinophil granules, can be secreted in phar- 
macologically active concentrations by highly purified eosino- 
phils. They indicate, moreover, that in vivo synthesis, as well 
as in vitro secretion, might differ according to the stimulus 
of activation of eosinophils. The release of IL-5 by eosinophils 
may participate to the local recruitment and activation during 
inflammatory diseases associated with eosinophilia. 
Materials and Methods 
Eosinophila.  Patients  with  a  massive  eosinophil  infiltration 
(>30%) were selected.  Bladder specimens were taken from a 47- 
yr-old woman who had presented several episodes of severe cystitis. 
Peripheral eosinophil  counts  were 840/mm  3.  Before treatment, 
histological examination revealed  an eosinophilic cystitis. 
Four patients with Crohn's disease  were selected for the pres- 
ence of numerous  eosinophils  infiltrating  intestinal  lesions (between 
20 and 40% of the infiltrating cells), whereas blood eosinophil 
counts were normal. 
Peripheral eosinophils were purified from the blood of six pa- 
tients fulfilling  the diagnostic  criteria  for idiopathic  h~sinophilic 
syndrome (HES): persistent eosinophilia  (>1.5 x  109/liter) for at 
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cause of  eosinophilia. The mean blood eosinophil  counts were 2.8 x 
109/liter with SD 1.4. By using discontinuous metrizamide gra- 
dients, hypodense  eosinophils, which sediment in the lightest den- 
sity, were isolated (7). After washing with HBSS, the degree of 
purity (90-99%)  was evaluated on cytocentrifuged preparations 
stained with Giemsa. After centrifugation, eosinophils were re- 
suspended in FIBSS  culture medium alone, without FCS, at a con- 
centration of 106 cells/m]. 
In Situ Hybridization.  Bladder  and intestinal specimens  were im- 
mediately fined in paraformaldehyde  4% in cacodylate  buffer and 
embedded in paraffin. In situ hybridization was performed as pre- 
viously described (4). Briefly,  the eDNA for human IL-5 was sub- 
cloned into the Blue Script vector by standard techniques. Linear- 
ized plasmid was used as the template for the synthesis in vitro 
of a 3sS-labeled RNA probe (Amersham-Franee,  Les Ullis, France) 
complementary  to the cellular  II,5 mRNA (antisense  probe). RNA 
was also transcribed in the opposite direction and used as a nega- 
tive control  (sense probe). Antisense or  sense probes (4,150 
cpm/mm  z) were hybridized with bladder and intestinal samples 
as previously described (4). To inhibit nonspecific  binding of 3sS, 
tissues were acetylated in triethanolamine 0.1 M, then in acetic 
anhydride  0.25 % triethanolamine for 10 min before hybridization. 
Further, to avoid  nonspecific  binding to eosinophils, prehybridiza- 
tion was carried out with a sohtion containing a nonradiolabeled 
S-UTP irrelevant  probe for at least  2 h at 42~  dithiothreitol  (DTY) 
was added to the hybridization buffer, and RNase A was used for 
posthybridization washings. After development of the emulsion, 
tissue sections were then stained with May Grfinwald Giemsa for 
examination by light microscopy. 
Immunohistochemistry.  To detect the presence of immunoreac- 
tire Ib5 in ensinophils, tissue paraffin sections or cytocentrifuged 
preparations of purified blood eosinophils were incubated with a 
mouse mAb (IgG1 isotype) directed against human IbS. This mAb 
(5A5) has a neutralizing effect on human IL-5, did not crossreact 
with mouse IbS, and has been purified on protein A-Sepharose 
(Van der Heyden,  J., T. Tuypens,  R. Devos, G. Plaetinck, Y. Guise'z, 
and J. Tavernier, manuscript in preparation). Bladder or intestinal 
sections and cytocentrifuged  preparations were washed in Tris-buf- 
fered saline (TBS), and anti-IL-5 mAb was added at a final concen- 
tration of 10 #g/m1. After incubation for 45 min at room tempera- 
ture, slides were briefly washed in TBS, and enzymatic complex, 
alkaline  phosphatase  anti-alkaline  phosphata~ (APAAP; Dak~ Glos- 
trap, Denmark) was added at 1:50 dilution, and developed with 
ASB1 phosphate substrate and neofuscin (Sigma  Chemical Co., St. 
Louis, MO) as previously  described (8). As control, a mAb of the 
same isotype but with a different specificity (anti-Echinococcus 
granulosus) was used with the same conditions. 
Immunogoid  Staining.  Bladder  specimens  were fixed  in glutaralde- 
hyde 2% in cacodyhte buffer, dehydrated,  and embedded at -35~ 
in Lowicryl K4M. Lowicryl sections were obtained as previously 
described (9). In brief, after saturation with heat-inactivated  normal 
rabbit  serum,  sections were incubated overnight at 40C  with 
anti-huraan II.~5 mAb at 50/~g/ml and diluted in TBS containing 
OVA (TIE-O). After washing with TBS-O and TBS, sections  were 
transferred on 15 am gold-conjugated rabbit and-mouse IgG so- 
lution (diluted 1:30;  Janssen  Life Science  Division, Berne, Belgium). 
After a 1-h incubation at room temperature, grids were washed 
with TBS and distilled water successively.  Lowicryl sections were 
stained with uranyl acetate and lead citrate. As controls, two mAbs 
of the same isotype were used in the same conditions: EG2, which 
recognizes the secreted form of eosinophil cationic protein (ECP) 
(10) (kindly given by Dr. P. C. Tai, St. George Hospital Medical 
School, London, UK), was used as positive control, and anti-IgA 
mAb (Immunotech, Marseilh Luminy,  France)  was used as a nega- 
tive control. The observations were made at 60 kW with a Zeiss 
EM 10 electron microscope. 
Eosinophil Activation.  Highly purified eosinophils (;>95% pu- 
rity) from patients  with hypereosinophilic  syndromes  were incubated 
in HBSS without serum for 24 h at 37~  and 5%  COz with 
recombinant human IL-3 (kindly donated by Sandoz Ltd., Basel, 
Switzerland) and recombinant human GM-CSF, a generous gift 
of Dr. J. Banchereau  (Schering Plough, Dardilly, France) at a final 
concentration of 10-9 M. 
Highly  purified eosinophils  from the six FIES patients were also 
incubated with serum IgA, secretory IgA (both purchased from 
Sigma Chemical Co.) and myeloma IgE protein (PS myeloma; a 
kind gift of  Dr. H. L. Spiegelberg, The Scripps Research Institute, 
LaJoUa, CA), or with human IgG (Sigma Chemical Co.) at a final 
concentration of 15 #g/ml in HBSS without serum. After a 1-h 
incubation at +4~  and without washing, eosinophils  were then 
stimulated at 37~  and 5% COz with the corresponding anti- 
IgA, anti-IgE, or anti-IgG mAb (Immunotech) at a concentration 
of 20 I~g/ml  for a period of time varying between 15 min and 18 h. 
The experiments were stopped by centrifugation of the tubes 
at 500g for 10 min at 4~  Supernatants were collected  and frozen 
at  -20~  until the ELISA could be performed. The cell pellets 
were resuspended at  a concentration of 0.8  x  106 cells/m] of 
FIBSS and loaded onto gehtin-coated slides (0.8  x  10  s ceils/slide) 
by cytocentrifugation.  The cytopreparations  were immediately  fixed 
in sterile acetone for 10 min and stored until analyzed for the pres- 
ence of immunoreactive IL-5 by immunocytochemistry. 
Measurement  of  lL5 in Supernatants.  ID5 levels  were determined 
by F_LISA as previously described (11). Briefly, serial dilutions of 
culture supernatants were incubated for two h at room tempera- 
ture in microweil modules (Maxisorps; Nunc, Rosldlde, Denmark) 
coated with 0.5/tg/m] of  the H30 rat anti-human IL-5  mAb IgG2b 
(provided by Dr. J.  Van der FIeyden, Roche Research). After 
washing, 0.1/~g of a mouse monoclonal anti-human Ib5 mAb 
IgG1 (mAbT; kindly provided by Glaxo Group Research Ltd., 
Greenford, Middlesex, UK) was added. Finally,  the binding of the 
latter mAb was revealed  by horseradish peroxidase-conjugated rat 
anti-mouse IgG1 mAb (LO MG1-2; Experimental Immunology 
Unit, Uuiversit6 Catholique de Louvain, Brussds, Belgium) fol- 
lowed by the appropriate substrate solution. Optical densities at 
450 nm were converted in pg/ml of IL-5 using a standard curve 
constructed with the recombinant human ID5 kindly provided by 
Roche Research. 
Results and Discuuion 
~e~ence ofIL-5 mRNA.  When bladder sections Im'form~ 
in a patient with eosinophilic cystitis were submitted to in 
situ hybridization, a strong positive signal was observ~ on 
numerous cells with the radiolabeled IL-5 antisense RNA 
probe (Hg. 1 A). Intestinal sections with massive eosinophilic 
infiltration, performed in the four patients with Crohn's dis- 
ease, were submitted to the same procedure. In contrast with 
bladder sections of the patient with eosinophih'c cystitis, only 
few ceUs showed a positive signal (Fig.  1 C). No signal was 
observed with the respective control sense probes (Fig.  1, B 
and D). 
Immunostaining with Anti-human IL-5 mAIL  To further 
characterize  the call population involved in the synthesis of 
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with  anti-human  IL-5  mAb  was  performed.  Using  the 
APAAP procedure, typical binucleated cells were positively 
stained (Fig.  1 E),  whereas no staining  was observed with 
the isotype control antibody (Fig. 1 F). Eosinophils were the 
only cell type with a polylobulated nucleus in these sections. 
A  similar procedure performed  on intestinal  sections from 
patients  with  Crohn's  disease revealed a positive immuno- 
staining  of mononuclear  cells only (data not  shown). 
Highly purified blood eosinophils could also be positively 
stained with anti-IL-5, but only after priming with IL-3 and 
GM-CSF (Fig. 2 A), whereas no staining was observed with 
medium  alone or on resting  eosinophils  (Fig.  2 B).  These 
results indicate that tissue eosinophils present in eosinophilic 
cystitis as well as ex vivo activated blood eosinophils could 
Figure  1.  Detection  of  II.-5 mRNA and 
protein in human eosinophils  by in situ hy- 
bridization and immunochemistry. (/1 and 
B) Bladder sections  of one patient with an 
eosinophilic cystitis. (C and D) Intestinal 
sections of patients with Crohn's disease. 
(A) Strong positive in situ hybridization 
with  a 3sS-labeled antisense Ib5  KNA 
probe on bladder sections  (exposure  time, 
10 d). (C) Weak  positive  in situ hybridiza- 
tion with the same  antisense  probe  (arrows) 
on intestinal sections  (exposure  time, 10 d). 
(B and D) With the sense control probe, 
no signal is observed  on bladder sections 
(B) or intestinal sections  (D). (E and F) IL-5 
immunostaining on tissue  sections. (E) Im- 
munophosphatase localization of IL-5 pro- 
tein in the ensinophilic cystitis. Note the 
presence  of  positively  labeled  cells  with bi- 
lobed nuclei (arrows). (F) With the irrele- 
vant antibody  (anti-Echinococcus  granulosus), 
no labeling is obtained. (x260). 
translate IL-5 mRNA,  whereas eosinophils in Crohn's dis- 
ease could not,  confirming  the results of in situ hybridiza- 
tion.  These findings confirm  and extend the recently pub- 
lished results (4-6) showing that eosinophils can transcribe 
IL-5 mRNA in coeliac disease, HES, asthma, or eosinophilic 
heart disease. However, they suggest that IL-5 expression by 
eosinophils is not observed in all diseases associated with mas- 
sive eosinophilic infiltration. 
A careful examination of eosinophils stained with the anti- 
IL-5 mAb revealed a heterogeneous labeling of the cytoplasm 
(Fig. 2 A), differing from the previously described immuno- 
staining for GM-CSF (12) but resembling the intracytoplasmic 
staining for IL-8 (13).  These findings led us to explore the 
subceUular localization  of IL-5 in eosinophils. 
Association of  lL.5 with Eosinophil Granules.  To localize IL-5 
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topreparations of purified blood eosinophils 
from patients with hypereosinophilic syn- 
dromes. (,'1)  Positive Ib5 immunostaining 
of peripheral  binudeated cells incubated 
with IL-3 and GM-CSF, note the hetero- 
geneous cytoplasmic immunophosphatase 
staining. (B) No signal is obtained when 
eosinophils  were  incubated  in  culture 
medium alone. (C-E). Kinetic studies of 
detection of immunoreactive IL-5  after IgA- 
dependent activation. (C) Intracytoplasmic 
immunostaining was observed when eo- 
sinophils  were incubated with IgA-anti-lgA 
for 15 rain. (D) After 2 h of incubation, 
IL-5 staining was located on the cell pe- 
riphery. (E) No more staining was observed 
when eosinophils were incubated  with the 
IgA immune complexes for 18 h.  x650. 
in eosinophils, immunogoldstaining with anti-IL-5 mAb re- 
vealed by means of gold-labeled anti-mouse rabbit antibodies 
and electron microscopy was performed on bladder sections 
embedded in Lowicryl.  As positive control, EG2,  a mAb 
which binds to ECP, located in granule matrix, was used. 
As shown in Fig. 3 A, the binding of anti-IL-5 mAb was 
concentrated  to granule matrix, similarly to EG2  staining 
(Fig. 3 C).  All examined eosinophils, and more than 70% 
Figure 3.  (A-C). Immunogold staining of Lowicryl embedded bladder 
sections of a patient with an eosinophilic cystitis. (A) More than 70% 
of the granules were labeled with the anti-human IIr  mAb (lyric nu- 
cleus, [LN])  x 12,375. (B) No staining when Lowicryl sections are in- 
cubated with an irrdevant mAb (anti-IgA).  x 7,875. (C) Positive control 
using anti-ECP  mAb (EG2).  x 10,625. 
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Figure 4.  IL-5-ELISA procedure on eosinophi] supernatants. Culture 
supernatants of r  from six different patients, activated for 18 h 
with  immune complc~.cs (sIgA-  or  IgA-anti-IgA, IgE-anti-lgE,  or 
IgG--anti-IgG), or with HBSS medium, were incubated in microplate walls 
coated with rat anti-human IL-5 mAh (H 30). After washing, a mouse 
anti-human Ib5 mAb (mAb 7) was added and its binding revealed by 
horseradish peroxidase-conjugated  rat anti-mouse mAb. Bars represent 
mean values obtained for six different eosinophil donors. of the granules were stained with the anti-human IL-5 mAb. 
No staining was obtained with the anti-IgA mAb used as 
negative control (Fig. 3 B). Eosinophils could therefore trans- 
late IL-5 mRNA and store the IL-5 protein in their granules. 
No precise identification of the localization of GM-CSF was 
given in the published study (12). However, the staining of 
eosinophil cytoplasm by the respective antibody suggested 
that GM-CSF localization or storage differed from IL-5. A 
similar granule localization has been reported for TNF-c~ in 
mast ceils (14). Upon activation, eosinophils may release IL-5 
more rapidly in the extracellular  space, upon degranulation, 
without neosynthesis. 
Synthesis and Secretion of IL-5 after Eosinophil Acti~tion. 
Since immobilized or cross-linked IgA is able to induce eo- 
sinophil degranulation (15, 16), we looked further at whether 
IgA-anti-IgA immune complexes could lead to IL-5 secre- 
tion. A kinetic study revealed that after activation of blood 
eosinophils with IgA immune comple~s for 15 rain at 37~ 
a positive intracyroplasmic staining with anti-IL-5 mAb was 
observed (Fig. 2 C). After 2 h of incubation, IL-5 staining 
was located on the periphery and the membrane of the majority 
of the cells, whereas few eosinophils still showed a cytoplasmic 
staining (Fig. 2 D). No staining could be observed after 18 h 
of incubation (Fig. 2 E). These results suggested that IL-5 
could be secreted by eosinophils. To confirm this hypothesis, 
the secretion of IL-5 by purified blood eosinophils after acti- 
vation with immune complexes,  was investigated by mea- 
surement of IL-5 in supernatants. 
The amounts of IL-5 were measured in the supernatants 
of highly purified eosinophils by the double sandwich ELISA 
procedure (Fig. 4). Significant  amounts of IL-5 were mea- 
sured in the supernatants of eosinophils after 18 h of activa- 
tion with serum or secretory IgA. IL-5 could also be secreted 
after IgE- or IgG-dependent activation, but with important 
variations,  according to the eosinophil donors. 
Our results indicate that ex vivo activation of eosinophils 
with immune complexes,  and principally IgA, consistently 
led to synthesis and secretion of the highest amounts of IL-5. 
They are in agreement with previous reports showing that 
IgA is the more potent stimulus for the release of granule 
proteins such as EDN (15), EPO, and ECP (16). Moreover, 
the localization of IL-5 associated with the role of insolubi- 
lized IgA in eosinophil degranulation might explain the de- 
tection of IL-5/n coeliac disease and eosinophilic cystitis where 
eosinophils are dosdy linked to IgA plasma cells (17, 18). 
In contrast, in coeliac disease with IgA deficiency, IL-5 was 
not detected in eosinophils (P. Desreumaux, personal com- 
munication) as well as in Crohn's disease, where IgM and 
IgG prevail (19). 
In view of our results, we suggest that a short incubation 
with immune complexes induced IL-5 expression,  whereas 
upon prolonged incubation, the secretion was initiated. Evi- 
dence for translation of IL-5 mtLNA into immunoreactive 
IL-5 by eosinophils from patients with various diseases was 
obtained by immunostaining with a specific mAb to human 
IL-5. A kinetic study of IL-5 immunodetection after activa- 
tion of eosinophils with IgA immune complexes in vitro 
confirmed the synthesis of IL-5 protein by eosinophils and 
ruled out a possible phagocytosis of exogenous IL-5. In addi- 
tion, the identification of picogram amounts of IL-5 in the 
supernatants of highly purified eosinophils only after activa- 
tion, provides evidence to support the fact that eosinophils 
can synthesize,  store,  and secrete IL-5. 
Activated T  ceUs remain the principal ceUular source of 
IL-5, but the synthesis and secretion of IL-5 by eosinophils 
may provide an important autocrine pathway that is involved 
in local eosinophil recruitment and activation. The synthesis 
of their own activating factors might explain the chronicity 
of lesions in diseases associated  with massive eosinophilic 
infiltration. 
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